Co-founders
J. Mark Junewicz, Founder and CEO
Stuart C. Sealfon, MD, Scientific Founder
Stuart C. Sealfon, MD, Scientific Founder
J. Mark Junewicz is an Executive in Residence at Mount Sinai Innovation Partners, the commercialization engine of the Mount Sinai Health System.
Mark is also the founder of Junewicz & Co. which provides financial and strategic advisory services to the Life Sciences industry (biopharma and medical device companies). He has extensive experi
J. Mark Junewicz is an Executive in Residence at Mount Sinai Innovation Partners, the commercialization engine of the Mount Sinai Health System.
Mark is also the founder of Junewicz & Co. which provides financial and strategic advisory services to the Life Sciences industry (biopharma and medical device companies). He has extensive experience in working with Life Sciences companies from start-up phase through successful exit. Previously Mark was a Managing Director and investment banker at Merrill Lynch and Bear Stearns.
Mark earned his BS Economics, cum laude, and MBA from The Wharton School of the University of Pennsylvania.
Stuart C. Sealfon, MD, Scientific Founder
Stuart C. Sealfon, MD, Scientific Founder
Stuart C. Sealfon, MD, Scientific Founder
Stuart C. Sealfon, MD, is the lead inventor of the $46 million DARPA ECHO contract. He is also GNOMX's Chief Scientific Officer and Chair of the Scientific Advisory Board.
Dr. Sealfon is the Glickenhaus Professor and Director of the Center for Advanced Research on Diagnostic Assays at the Icahn School of Medicine at Mount Sinai (ISMMS). A
Stuart C. Sealfon, MD, is the lead inventor of the $46 million DARPA ECHO contract. He is also GNOMX's Chief Scientific Officer and Chair of the Scientific Advisory Board.
Dr. Sealfon is the Glickenhaus Professor and Director of the Center for Advanced Research on Diagnostic Assays at the Icahn School of Medicine at Mount Sinai (ISMMS). A renowned systems biologist, he is Chairman emeritus of the ISMMS Neurology Department and author of >200 patents and research publications and COVID-19 clinical and basic research studies.
A graduate of Princeton University and Columbia University College of Physicians and Surgeons, Dr. Sealfon in a member of Phi Beta Kappa and Alpha Omega Alpha. He received his residency training at Massachusetts General Hospital. He has been associated with the ISMMS for more than two decades.
scientific advisory board
John N. Aucott, MD
Captain Andrew Letizia, MD, US Navy
Captain Andrew Letizia, MD, US Navy
Dr. John Aucott is The Barbara Townsend Cromwell Professor in Lyme Disease and Tick-borne Illness Associate Professor of Medicine, Johns Hopkins University School of Medicine. He is Director of the Johns Hopkins Lyme Disease Research Center
Dr. Aucott has been involved in care of patients and research in Lyme disease since joining the Joh
Dr. John Aucott is The Barbara Townsend Cromwell Professor in Lyme Disease and Tick-borne Illness Associate Professor of Medicine, Johns Hopkins University School of Medicine. He is Director of the Johns Hopkins Lyme Disease Research Center
Dr. Aucott has been involved in care of patients and research in Lyme disease since joining the Johns Hopkins faculty in 1996. He assumed the position of Director of the Johns Hopkins Lyme Disease Research Center in April 2015 and is an Associate Professor of Medicine at the Johns Hopkins University School of Medicine, Division of Rheumatology. In 2023, he became the inaugural recipient of the Barbara Townsend Cromwell Professor in Lyme Disease and Tick-borne Illness.
Dr. Aucott received his undergraduate degree in molecular biology from the University of California at Berkeley and his MD from the Johns Hopkins University School of Medicine. He trained at University Hospitals of Cleveland and is a diplomate of the American Board of Internal Medicine with board certification in Infectious Diseases.
Captain Andrew Letizia, MD, US Navy
Captain Andrew Letizia, MD, US Navy
Captain Andrew Letizia, MD, US Navy
Captain Andrew G. Letizia, MD, US Navy, is the science director at Naval Medical Research Unit 2–Singapore.
Dr. Letizia is a US military infectious disease expert and COVID-19 authority. He led the groundbreaking Covid Health Action Response in Marines (CHARM) study.
Dr. Letizia received his medical degree from Icahn School of Medicine
Captain Andrew G. Letizia, MD, US Navy, is the science director at Naval Medical Research Unit 2–Singapore.
Dr. Letizia is a US military infectious disease expert and COVID-19 authority. He led the groundbreaking Covid Health Action Response in Marines (CHARM) study.
Dr. Letizia received his medical degree from Icahn School of Medicine at Mount Sinai and has been in practice for more than 20 years.
Olga Troyanskaya, PhD
Captain Andrew Letizia, MD, US Navy
Olga Troyanskaya, PhD
Olga Troyanskaya, PhD, co-inventor, is Professor of Computer Science at Princeton University and Deputy director of the Genomics Flatiron Institute. Dr. Troyanskaya was awarded one of the top young technology innovators by the MIT Technology Review and Sloan Research Fellowship. She is also on the Scientific Advisory Board of Caris Life S
Olga Troyanskaya, PhD, co-inventor, is Professor of Computer Science at Princeton University and Deputy director of the Genomics Flatiron Institute. Dr. Troyanskaya was awarded one of the top young technology innovators by the MIT Technology Review and Sloan Research Fellowship. She is also on the Scientific Advisory Board of Caris Life Sciences.
Dr. Troyanskaya has a bachelor's degree in computer science and biology from the University of Richmond and a PhD in Biomedical Informatics from Stanford University.